Literature DB >> 15340094

Tesio-Caths provide effective and safe long-term vascular access.

Neill D C Duncan1, Seema Singh, Thomas D H Cairns, Martin Clark, Adil El-Tayar, Megan Griffith, Nadey Hakim, Mohamad Hamady, Adam G McLean, Vassilios Papalois, Andrew Palmer, David Taube.   

Abstract

BACKGROUND: Vascular access is judged on its ability to provide good dialysis adequacy, its durability and complication rates. Formation of a functional arteriovenous fistula is desirable but difficult to achieve in a significant proportion of patients. We report the large-scale use of Tesio-Caths, a twin-line single-lumen central venous catheter, to maximize dialysis adequacy where formation of an arteriovenous fistula was not possible.
METHODS: All patients who had Tesio-Caths inserted between 1 January 1999 and 1 October 2002 were studied.
RESULTS: Six hundred and twenty-three Tesio-Caths were inserted from 1 January 1999 to 1 October 2002 in 435 patients, generating 7464 patient months of follow-up. Five hundred and ninety-four out of 623 (95.3%) Tesio-Caths were immediately functional. Mean dialysis adequacy measured by single-pool Kt/V was 1.5+/-0.3 for all Tesio-Caths for the entire period of study, with 68% of Tesio-Caths delivering a Kt/V >1.4. Cumulative functional Tesio-Cath survival to final failure was 77.8 and 44% at 1 and 3 years, respectively. Cumulative patient survival was 84.7, 71.4 and 63% at 1, 2 and 3 years, respectively. Access-related infection accounted for 0.28 admissions/1000 catheter days, and the death rate from access-related sepsis was 9.6 deaths/1000 patient years at risk. The admission rate for access dysfunction was 0.33/1000 patient years at risk.
CONCLUSION: Tesio-Caths provide good dialysis adequacy for patients in whom an arteriovenous fistula cannot be formed. Patient and functional access survival for this group was comparable with current European data irrespective of vascular access type. Complication rates were acceptably low.

Entities:  

Mesh:

Year:  2004        PMID: 15340094     DOI: 10.1093/ndt/gfh467

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  7 in total

1.  Patency and Complications of Translumbar Dialysis Catheters.

Authors:  Fanna Liu; Stacy Bennett; Susana Arrigain; Jesse Schold; Robert Heyka; Gordon McLennan; Sankar D Navaneethan
Journal:  Semin Dial       Date:  2015-03-20       Impact factor: 3.455

Review 2.  [Dialysis patients in intensive care units].

Authors:  H P Kierdorf
Journal:  Med Klin Intensivmed Notfmed       Date:  2013-03-17       Impact factor: 0.840

3.  Bacteremia associated with tunneled hemodialysis catheters: outcome after attempted salvage.

Authors:  Damien R Ashby; Albert Power; Seema Singh; Peter Choi; David H Taube; Neill D Duncan; Tom D Cairns
Journal:  Clin J Am Soc Nephrol       Date:  2009-08-13       Impact factor: 8.237

4.  Computed Tomography (CT)-Navigated Translumbar Hemodialysis Catheters: A 10-Year Single-Center Experience.

Authors:  Tomas Jonszta; Daniel Czerny; Vaclav Prochazka; Adela Vrtkova; Vendelin Chovanec; Antonin Krajina
Journal:  Med Sci Monit       Date:  2020-12-15

5.  Tissue plasminogen activator versus heparin for locking dialysis catheters: A systematic review.

Authors:  Belal M Firwana; Rim Hasan; Mazen Ferwana; Joseph Varon; Aaron Stern; Umesh Gidwani
Journal:  Avicenna J Med       Date:  2011-10

6.  Vascular access use and outcomes: an international perspective from the Dialysis Outcomes and Practice Patterns Study.

Authors:  Jean Ethier; David C Mendelssohn; Stacey J Elder; Takeshi Hasegawa; Tadao Akizawa; Takashi Akiba; Bernard J Canaud; Ronald L Pisoni
Journal:  Nephrol Dial Transplant       Date:  2008-05-29       Impact factor: 5.992

7.  Tunnelled haemodialysis catheter and haemodialysis outcomes: a retrospective cohort study in Zagreb, Croatia.

Authors:  Vedran Pašara; Bojana Maksimović; Mihaela Gunjača; Karlo Mihovilović; Andrea Lončar; Boris Kudumija; Igor Žabić; Mladen Knotek
Journal:  BMJ Open       Date:  2016-05-17       Impact factor: 2.692

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.